| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.07 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.07 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.059 | 0.07 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | 0.52 | 0.07 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.07 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.059 | 0.07 |